How I treat primary CNS lymphoma

Area of Science:

• Neuro-oncology
• Hematology
• Translational Medicine

Background:

• Primary CNS lymphoma (PCNSL) is a rare, aggressive brain malignancy with poor prognosis.
• Treatment challenges include incomplete molecular understanding, the tumor microenvironment, and treatment-related neurotoxicity.
• Difficulties in conducting clinical trials due to rarity and patient condition limit evidence-based guidelines.

Purpose of the Study:

• To analyze recent advancements in PCNSL biology and treatment.
• To provide evidence-based recommendations for clinical practice.
• To outline the rationale for future clinical trials in PCNSL.

Main Methods:

• Review and analysis of recent studies on PCNSL biology and molecular mechanisms.
• Evaluation of data from the first international randomized trials for PCNSL.
• Synthesis of findings to inform clinical practice and trial design.

Main Results:

• Recent research has shed light on PCNSL biology and molecular targets.
• International randomized trials are providing higher-level evidence for treatment strategies.
• Understanding the tumor microenvironment is crucial for improving treatment efficacy.

Conclusions:

• Despite challenges, coordinated research efforts are improving understanding and treatment of PCNSL.
• New data support refined clinical recommendations and the design of future trials.
• Addressing neurotoxicity and optimizing treatment intensity remain critical.